Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Income towards Parent Company (2016 - 2025)

China Pharma Holdings filings provide 16 years of Income towards Parent Company readings, the most recent being -$1.2 million for Q4 2025.

  • On a quarterly basis, Income towards Parent Company changed 0.19% to -$1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.2 million, a 32.7% increase, with the full-year FY2025 number at -$3.2 million, up 32.7% from a year prior.
  • Income towards Parent Company hit -$1.2 million in Q4 2025 for China Pharma Holdings, down from -$651482.0 in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of -$475976.0 in Q1 2023 to a low of -$1.4 million in Q2 2024.
  • Median Income towards Parent Company over the past 5 years was -$857531.5 (2021), compared with a mean of -$918752.8.
  • Biggest five-year swings in Income towards Parent Company: plummeted 6418.56% in 2021 and later soared 63.26% in 2025.
  • China Pharma Holdings' Income towards Parent Company stood at -$980719.0 in 2021, then dropped by 28.9% to -$1.3 million in 2022, then increased by 2.53% to -$1.2 million in 2023, then grew by 0.63% to -$1.2 million in 2024, then rose by 0.19% to -$1.2 million in 2025.
  • The last three reported values for Income towards Parent Company were -$1.2 million (Q4 2025), -$651482.0 (Q3 2025), and -$528367.0 (Q2 2025) per Business Quant data.